Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in advanced pancreatic ductal adenocarcinoma: a retrospective real-world analysis
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest solid tumors. Patients who develop PDAC with locally advanced pancreatic cancer (LAPC) or metastases have an especially poor prognosis[1][1]. Although there have been improvements in systemic therapy, long-term disease control is
Authors
- Rentao Li
- H. Li
- Yi Liu (ORCID: https://orcid.org/0000-0001-6109-5347)
- Hao Wang (ORCID: https://orcid.org/0000-0001-6881-9977)
- Rui Xia (ORCID: https://orcid.org/0000-0002-2503-0041)
- Jihui Hao (ORCID: https://orcid.org/0000-0002-5598-6706)
- Xihao Zhang
- Yanmei Ou
- Dandan Wu
- Xing Li
- Chuntao Gao
- Tongguo Si
- Yong Xu
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2026-03-16
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2025.0848
- Primary Topic
- Microbial Inactivation Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tianjin Medical University
- Tianjin Municipal Science and Technology Bureau
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences